Literature DB >> 18230054

An update on huperzine A as a treatment for Alzheimer's disease.

John T Little1, Sally Walsh, Paul S Aisen.   

Abstract

Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment for AD, including the Phase II trial now under way in the US.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230054     DOI: 10.1517/13543784.17.2.209

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  14 in total

1.  Synthesis of (±)-7-hydroxylycopodine.

Authors:  Hong-Yu Lin; Barry B Snider
Journal:  Org Lett       Date:  2011-01-27       Impact factor: 6.005

Review 2.  Huperzine A for vascular dementia.

Authors:  Zilong Hao; Ming Liu; Zhiqin Liu; Donghao Lv
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

3.  Synthesis of (±)-7-hydroxylycopodine.

Authors:  Hong-Yu Lin; Robert Causey; Gregory E Garcia; Barry B Snider
Journal:  J Org Chem       Date:  2012-03-30       Impact factor: 4.354

4.  A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Authors:  M S Rafii; S Walsh; J T Little; K Behan; B Reynolds; C Ward; S Jin; R Thomas; P S Aisen
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

5.  Treatment of Mild Cognitive Impairment.

Authors:  Brendan J Kelley
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

6.  Acetylcholinesterase-independent protective effects of huperzine A against iron overload-induced oxidative damage and aberrant iron metabolism signaling in rat cortical neurons.

Authors:  Ling-Xue Tao; Xiao-Tian Huang; Yu-Ting Chen; Xi-Can Tang; Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

7.  Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

Authors:  Bai-Song Wang; Hao Wang; Zhao-Hui Wei; Yan-Yan Song; Lu Zhang; Hong-Zhuan Chen
Journal:  J Neural Transm (Vienna)       Date:  2009-02-17       Impact factor: 3.575

Review 8.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.

Authors:  Raj N Kalaria; Gladys E Maestre; Raul Arizaga; Robert P Friedland; Doug Galasko; Kathleen Hall; José A Luchsinger; Adesola Ogunniyi; Elaine K Perry; Felix Potocnik; Martin Prince; Robert Stewart; Anders Wimo; Zhen-Xin Zhang; Piero Antuono
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

Review 9.  Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis.

Authors:  Shu-Huai Xing; Chun-Xiao Zhu; Rui Zhang; Li An
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-03       Impact factor: 2.629

10.  New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.

Authors:  Si-Yuan Pan; Shu-Feng Zhou; Si-Hua Gao; Zhi-Ling Yu; Shuo-Feng Zhang; Min-Ke Tang; Jian-Ning Sun; Dik-Lung Ma; Yi-Fan Han; Wang-Fun Fong; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.